Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: Role of D3 and not D2 receptors

Brain Research

Volumn 955, Issue 1-2, 2002, Pages 138-152

  Joyce, J N ^a   Ryoo, H L ^a   Beach, T B ^a   Caviness, J N ^b   Stacy, Mark ^c   Gurevich, E V ^a   Reiser, Mark ^d   Adler, C H ^b  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c Muhammad Ali Parkinson Center   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Dopamine D3 receptor; Parkinson's disease

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; LEVODOPA; METHYLPHENIDATE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; TYROSINE 3 MONOOXYGENASE;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEMENTIA; DOPAMINERGIC SYSTEM; FEMALE; GLOBUS PALLIDUS; HISTORY OF MEDICINE; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NEUROPATHOLOGY; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CORPUS STRIATUM; DEMENTIA; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; RETROSPECTIVE STUDIES; RNA, MESSENGER; TYROSINE 3-MONOOXYGENASE;

EID: 0037111151     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03396-6     Document Type: Article

References (82)

1. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease, The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease, Neurobiol. Aging 18 (1997) S1-S2.
2. Altar C.A., Cai N., Bliven T., Juhasz M., Conner J.M., Acheson A.L., Lindsay R.M., Wiegand S.J. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 389:1997;856-860.
3. Antonini A., Schwarz J., Oertel W.H., Pogarell O., Leenders K.L. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov. Disord. 12:1997;33-38.
4. Antonini A., Vontobel P., Psylla M., Gunther I., Maguire P.R., Missimer J., Leenders K.L. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch. Neurol. 52:1995;1183-1190.
5. Apaydin H., Ahlskog J.E., Parisi J.E., Boeve B.F., Dickson D.W. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch. Neurol. 59:2002;102-112.
6. Asenbaum S., Brucke T., Pirker W., Podreka I., Angelberger P., Wenger S., Wober C., Muller C., Deecke L. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J. Nucl. Med. 38:1997;1-6.
7. Blanchet P.J., Konitsiotis S., Chase T.N. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. J. Pharmacol. Exp. Ther. 283:1997;794-799.
8. Bokobza B., Ruberg M., Scatton B., Javoy-Agid F., Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. Eur. J. Pharmacol. 99:1984;167-175.
9. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. (Berl.). 82:1991;239-259.
10. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 68:2000;685-689.
11. Brooks D.J., Ibanez V., Sawle G.V., Playford E.D., Quinn N., Mathias C.J., Lees A.J., Marsden C.D., Bannister R., Frackowiak R.S. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann. Neurol. 31:1992;184-192.
12. Brucke T., Asenbaum S., Pirker W., Djamshidian S., Wenger S., Wober C., Muller C., Podreka I. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J. Neural Transm. Suppl. 50:1997;9-24.
13. Caparros-Lefebvre D., Pecheux N., Petit V., Duhamel A., Petit H. Which factors predict cognitive decline in Parkinson's disease? J. Neurol. Neurosurg. Psychiatry. 58:1995;51-55.
14. Chinaglia G., Alvarez F.J., Probst A., Palacios J.M. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. Neuroscience. 49:1992;317-327.
15. Churchyard A., Lees A.J. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson's disease [see comments]. Neurology. 49:1997;1570-1576.
16. Civelli O., Bunzow J.R., Grandy D.K. Molecular diversity of the dopamine receptors. Annu. Rev. Pharmacol. Toxicol. 33:1993;281-307.
17. Cordato N.J., Halliday G.M., Harding A.J., Hely M.A., Morris J.G. Regional brain atrophy in progressive supranuclear palsy and Lewy body disease. Ann. Neurol. 47:2000;718-728.
18. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain. 122:(8):1999;1421-1436.
19. Damier P., Hirsch E.C., Agid Y., Graybiel A.M. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain. 122:(8):1999;1437-1448.
20. Daniel S.E., Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J. Neural Transm. Suppl. 39:1993;165-172.
21. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann. Neurol. 24:1988;366-371.
22. S.A. Factor, Dopamine agonists, Med. Clin. North Am. 83 (1999) 415-vii.
23. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 114:(5):1991;2283-2301.
24. Frost J.J., Rosier A.J., Reich S.G., Smith J.S., Ehlers M.D., Snyder S.H., Ravert H.T., Dannals R.F. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease [see comments]. Ann. Neurol. 34:1993;423-431.
25. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 56:1999;33-39.
26. German D.C., Manaye K., Smith W.K., Woodward D.J., Saper C.B. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann. Neurol. 26:1989;507-514.
27. 3 receptor expression and triggers behavioural sensitization. Nature. 411:2001;86-89.
28. 3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry. 54:1997;225-232.
29. 2 receptor expressing neurons. Neuropsychopharmacology. 20:1999;60-80.
30. Guttman M., Seeman P., Reynolds G.P., Riederer P., Jellinger K., Tourtellotte W.W. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann. Neurol. 19:1986;487-492.
31. Haber S.N., McFarland N.R. The concept of the ventral striatum in nonhuman primates. Ann. NY Acad. Sci. 877:1999;33-48.
32. 3 receptor agonist/antagonist in primate model of Parkinson's disease (Abstr.). Soc. Neurosci. 25:(2):1999;1598.
33. Hagglund J., Aquilonius S.M., Eckernas S.A., Hartvig P., Lundquist H., Gullberg P., Langstrom B. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone. Acta Neurol. Scand. 75:1987;87-94.
34. Hornykiewicz O. Biochemical aspects of Parkinson's disease. Neurology. 51:1998;S2-S9.
35. Hughes T.A., Ross H.F., Musa S., Bhattacherjee S., Nathan R.N., Mindham R.H., Spokes E.G. A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology. 54:2000;1596-1602.
36. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M., Arnold S.E. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology. 54:2000;1916-1921.
37. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 14:1991;153-197.
38. Jellinger K.A., Paulus W. Clinico-pathological correlations in Parkinson's disease. Clin. Neurol. Neurosurg. 94:(Suppl.):1992;S86-S88.
39. Joyce J.N. Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. III. Results in Parkinson's disease cases. Brain Res. 600:1993;156-160.
40. 3 receptors are elevated after 9 or 11 months chronic haloperidol treatment: Influence of withdrawal period. Synapse. 40:2001;137-144.
41. 3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol. Ther. 90:2001;231-259.
42. 125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. J. Pharmacol. Exp. Ther. 257:1991;1253-1263.
43. Joyce J.N., Smutzer G., Whitty C.J., Myers A., Bannon M.J. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease. Mov. Disord. 12:1997;885-897.
44. 3 receptors with degeneration of the dopamine system. Neuroreport. 11:2000;2173-2175.
45. Lévesque D., Martres M.P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA. 92:1995;1719-1723.
46. Loschmann P.A., Smith L.A., Lange K.W., Jahnig P., Jenner P., Marsden C.D. Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets. Psychopharmacology (Berl.). 109:1992;49-56.
47. 125I-IABN, a novel azabicyclononane benzamide selective for D2-like dopamine receptors. Synapse. 38:2000;438-449.
48. Ma S.Y., Roytta M., Rinne J.O., Collan Y., Rinne U.K. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J. Neurol. Sci. 151:1997;83-87.
49. Marder K., Tang M.X., Cote L., Stern Y., Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch. Neurol. 52:1995;695-701.
50. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., Oakes D., Seibyl J. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology. 57:2001;2089-2094.
51. Marek K., Seibyl J., Shoulson I., Holloway R., Kieburtz K., McDermott M., Kamp C., Shinaman A., Fahn S., Lang A., Weiner W., Welsh M. Dopamine transporter brain imaging to assess the effects of pramipexole vs. levodopa on Parkinson disease progression. J. Am. Med. Assoc. 287:2002;1653-1661.
52. Mattila P.M., Rinne J.O., Helenius H., Dickson D.W., Roytta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol. (Berl.). 100:2000;285-290.
53. McKeith I.G., Galasko D., Kosaka K., Perry E.K., Dickson D.W., Hansen L.A., Salmon D.P., Lowe J., Mirra S.S., Byrne E.J., Lennox G., Quinn N.P., Edwardson J.A., Ince P.G., Bergeron C., Burns A., Miller B.L., Lovestone S., Collerton D., Jansen E.N., Ballard C., de Vos R.A., Wilcock G.K., Jellinger K.A., Perry R.H. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 47:1996;1113-1124.
54. McRitchie D.A., Cartwright H.R., Halliday G.M. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp. Neurol. 144:1997;202-213.
55. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 41:1991;479-486.
56. Morrish P.K., Sawle G.V., Brooks D.J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain. 119:(2):1996;585-591.
57. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann. Neurol. 24:1988;372-378.
58. 2 receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. USA. 91:1994;11271-11275.
59. Murray A.M., Weihmueller F.B., Marshall J.F., Hurtig H.I., Gottleib G.L., Joyce J.N. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol. 37:1995;300-312.
60. Müller Th., Farahati J., Kuhn W., Eising E.G., Przuntek H., Reiners C., Coenen H.H. [123I]beta-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur. Neurol. 39:1998;44-48.
61. Narabayashi H. The neural mechanisms and progressive nature of symptoms of Parkinson's disease - based on clinical, neurophysiological and morphological studies. J. Neural Transm. Parkinson's Dis. Dementia Sect. 10:1995;63-75.
62. Nomoto M., Jenner P., Marsden C.D. The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset. Neurosci. Lett. 57:1985;37-41.
63. Parain K., Murer M.G., Yan Q., Faucheux B., Agid Y., Hirsch E., Raisman-Vozari R. Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra. Neuroreport. 10:1999;557-561.
64. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Burn D., Johnson M., Perry R.H., McKeith I.G., Ballard C., Perry E.K. Striatal dopaminergic markers in dementia with lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 122:(8):1999;1449-1468.
65. Piggott M.A., Marshall E.F., Thomas N., Lloyd S., Court J.A., Jaros E., Costa D., Perry R.H., Perry E.K. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine. Neuroscience. 90:1999;433-445.
66. Pizzolato G., Chierichetti F., Rossato A., Cagnin A., Fabbri M., Dam M., Ferlin G., Battistin L. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study. J. Neural Transm. Suppl. 45:1995;113-122.
67. Police S., He L., Di Monte D., Langston J.W., Quik M. Alterations in D3 receptors in monkey caudate after MPTP and L-dopa treatments. Soc. Neurosci. Abstr. 25:1999;330.
68. Portin R., Rinne U.K. Predictive factors for cognitive deterioration and dementia in Parkinson's disease. Adv. Neurol. 45:1987;413-416.
69. 3 receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment. Neuroscience. 98:2000;263-273.
70. Rezaie P., Cairns N.J., Chadwick A., Lantos P.L. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci. Lett. 212:1996;111-114.
71. Rinne J.O., Bergman J., Ruottinen H., Haaparanta M., Eronen E., Oikonen V., Sonninen P., Solin O. Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease. Synapse. 31:1999;119-124.
72. Rinne J.O., Laihinen A., Lonnberg P., Marjamaki P., Rinne U.K. A post-mortem study on striatal dopamine receptors in Parkinson's disease. Brain Res. 556:1991;117-122.
73. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13:1998;788-797.
74. Schmidt M.L., Martin J.A., Lee V.M., Trojanowski J.Q. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders. Acta Neuropathol. (Berl.). 91:1996;475-481.
75. Seeman P., Bzowej N.H., Guan H.C., Bergeron C., Reynolds G.P., Bird E.D., Riederer P., Jellinger K., Tourtellotte W.W. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. 1:1987;5-15.
76. Seibyl J.P., Marek K.L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., Baldwin R.M., Fussell B., Smith E.O., Charney D.S. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38:1995;589-598.
77. 3) as a target for neuroleptics. Nature. 347:1990;146-151.
78. Stern Y., Marder K., Tang M.X., Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology. 43:1993;1690-1692.
79. Tissingh G., Bergmans P., Booij J., Winogrodzka A., van Royen E.A., Stoof J.C., Wolters E.C. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J. Neurol. 245:1998;14-20.
80. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 43:1998;555-560.
81. 1 receptor agonists. The way forward for the treatment of Parkinson's Disease? CNS Drugs. 11:1999;83-91.
82. Zweig R.M., Jankel W.R., Hedreen J.C., Mayeux R., Price D.L. The pedunculopontine nucleus in Parkinson's disease. Ann. Neurol. 26:1989;41-46.